HLA-C and neoplasm: Compared with neoHELP, vaccination with neoHELP_CD8wt or neoHELP_CD4wt significantly reduced survival from 100% to 20%–30% (Figure 5C), revealing that both MHC class I- and class II-restricted neoantigens were crucial for tumor control.